Our results suggest SARS-CoV-2 may continue to circulate among humans despite herd immunity due to natural infection. Compared to viral genomes in GISAID, the first virus genome was phylogenetically closely related to strains collected in March/April 2020, while the second virus genome was closely related to strains collected in July/August 2020.Įpidemiological, clinical, serological, and genomic analyses confirmed that the patient had re-infection instead of persistent viral shedding from first infection. Another 23 nucleotide and 13 amino acid differences located in 9 different proteins, including positions of B and T cell epitopes, were found between viruses from the first and second episodes. The virus genome from the first episode contained a a stop codon at position 64 of ORF8, leading to a truncation of 58 amino acids. Viral genomes from first and second episodes belong to different clades/lineages. During the second episode, there was evidence of acute infection including elevated C-reactive protein and SARS-CoV-2 IgG seroconversion. The second episode of asymptomatic infection occurred 142 days after the first symptomatic episode in an apparently immunocompetent patient. Laboratory results, including RT-PCR Ct values and serum Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) IgG, were analyzed. Comparative genome analysis was conducted to differentiate re-infection from persistent viral shedding. Whole genome sequencing was performed directly on respiratory specimens collected during 2 episodes of COVID-19 in a patient. However, it remains unclear whether true re-infection occurs. Waning immunity occurs in patients who have recovered from Coronavirus Disease 2019 (COVID-19).
5 Department of Accident and Emergency, North Lantau Hospital, Hong Kong Special Administrative Region, China.4 Department of Accident and Emergency Medicine, Tin Shui Wai Hospital, Hong Kong Special Administrative Region, China.3 Department of Medicine, Queen Mary Hospital, Hong Kong Special Administrative Region, China.
2 Department of Microbiology, Queen Mary Hospital, Hong Kong Special Administrative Region, China.1 State Key Laboratory for Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, China.
0 kommentar(er)
